tetano
Editor, Senior Moderator
Clin Infect Dis
. 2023 Jan 5;ciac982.
doi: 10.1093/cid/ciac982. Online ahead of print.
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses
Kathleen M Neuzil[SUP] 1 [/SUP], Evan J Anderson[SUP] 2 [/SUP], Robert W Frenck[SUP] 3 [/SUP], Sharon E Frey[SUP] 4 [/SUP], Emmanuel B Walter[SUP] 5 [/SUP], Richard Rupp[SUP] 6 [/SUP], Elizabeth T Rotrosen[SUP] 1 [/SUP], Nadine G Rouphael[SUP] 7 [/SUP], Rebecca C Brady[SUP] 3 [/SUP], Irene Graham[SUP] 4 [/SUP], Kenneth E Schmader[SUP] 8 [/SUP], Laura Porterfield[SUP] 9 [/SUP], Justin R Ortiz[SUP] 1 [/SUP], Geeta K Swamy[SUP] 10 [/SUP], Hana M El Sahly[SUP] 11 [/SUP], Trushar Jeevan[SUP] 12 [/SUP], Ranjan Sitaula[SUP] 13 [/SUP], Ashley Wegel[SUP] 13 [/SUP], Richard J Webby[SUP] 12 [/SUP], Christopher Bryant[SUP] 13 [/SUP]; Influenza A/H5N8 Virus Vaccine Group
Collaborators, Affiliations
Abstract
Background: Influenza A/H5N8 viruses infect poultry and wild birds in many countries. In 2021, the first human A/H5N8 cases were reported.
Methods: We conducted a phase I, cohort-randomized, double-blind, controlled trial of inactivated influenza A/H5N8 vaccine (clade 2.3.4.4c) administered with or without adjuvant. Cohort 1 subjects received either two doses of AS03-adjuvanted vaccine containing 3.75 μg or 15 μg hemagglutinin (HA); two doses of 15 μg HA unadjuvanted vaccine; or one dose of AS03-adjuvanted vaccine (3.75 μg or 15 μg HA), followed by one dose of non-adjuvanted vaccine (same HA content). Cohort 2 subjects received two doses of MF59-adjuvanted vaccine containing 3.75 μg or 15 μg HA, or 15 μg HA of non-adjuvanted vaccine. Subjects were followed for 13 months for safety and immunogenicity.
Results: We enrolled 386 adult subjects in good health. Solicited adverse events were generally mild and more common among subjects who received adjuvanted vaccines. Antibody responses (hemagglutination inhibition or microneutralization assays) were highest in the two-dose AS03 group, followed by the one-dose AS03 group, the MF59 groups, and the non-adjuvanted groups. Antibody levels returned to baseline 12 months after the second vaccination in all groups except the 15 μg AS03-adjuvanted group. Cross-reactive antibodies to clade 2.3.4.4b strains isolated from recent human cases were demonstrated in a subset of both 15 μg adjuvanted groups.
Conclusions: Two doses of influenza A/H5N8 vaccine were well-tolerated. Immunogenicity improved with receipt of two doses of adjuvanted vaccine and higher antigen content. (Funded by the National Institute of Allergy and Infectious Diseases.
Keywords: adjuvants; avian influenza; immunogenicity; influenza vaccine.
. 2023 Jan 5;ciac982.
doi: 10.1093/cid/ciac982. Online ahead of print.
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses
Kathleen M Neuzil[SUP] 1 [/SUP], Evan J Anderson[SUP] 2 [/SUP], Robert W Frenck[SUP] 3 [/SUP], Sharon E Frey[SUP] 4 [/SUP], Emmanuel B Walter[SUP] 5 [/SUP], Richard Rupp[SUP] 6 [/SUP], Elizabeth T Rotrosen[SUP] 1 [/SUP], Nadine G Rouphael[SUP] 7 [/SUP], Rebecca C Brady[SUP] 3 [/SUP], Irene Graham[SUP] 4 [/SUP], Kenneth E Schmader[SUP] 8 [/SUP], Laura Porterfield[SUP] 9 [/SUP], Justin R Ortiz[SUP] 1 [/SUP], Geeta K Swamy[SUP] 10 [/SUP], Hana M El Sahly[SUP] 11 [/SUP], Trushar Jeevan[SUP] 12 [/SUP], Ranjan Sitaula[SUP] 13 [/SUP], Ashley Wegel[SUP] 13 [/SUP], Richard J Webby[SUP] 12 [/SUP], Christopher Bryant[SUP] 13 [/SUP]; Influenza A/H5N8 Virus Vaccine Group
Collaborators, Affiliations
- PMID: 36610728
- DOI: 10.1093/cid/ciac982
Abstract
Background: Influenza A/H5N8 viruses infect poultry and wild birds in many countries. In 2021, the first human A/H5N8 cases were reported.
Methods: We conducted a phase I, cohort-randomized, double-blind, controlled trial of inactivated influenza A/H5N8 vaccine (clade 2.3.4.4c) administered with or without adjuvant. Cohort 1 subjects received either two doses of AS03-adjuvanted vaccine containing 3.75 μg or 15 μg hemagglutinin (HA); two doses of 15 μg HA unadjuvanted vaccine; or one dose of AS03-adjuvanted vaccine (3.75 μg or 15 μg HA), followed by one dose of non-adjuvanted vaccine (same HA content). Cohort 2 subjects received two doses of MF59-adjuvanted vaccine containing 3.75 μg or 15 μg HA, or 15 μg HA of non-adjuvanted vaccine. Subjects were followed for 13 months for safety and immunogenicity.
Results: We enrolled 386 adult subjects in good health. Solicited adverse events were generally mild and more common among subjects who received adjuvanted vaccines. Antibody responses (hemagglutination inhibition or microneutralization assays) were highest in the two-dose AS03 group, followed by the one-dose AS03 group, the MF59 groups, and the non-adjuvanted groups. Antibody levels returned to baseline 12 months after the second vaccination in all groups except the 15 μg AS03-adjuvanted group. Cross-reactive antibodies to clade 2.3.4.4b strains isolated from recent human cases were demonstrated in a subset of both 15 μg adjuvanted groups.
Conclusions: Two doses of influenza A/H5N8 vaccine were well-tolerated. Immunogenicity improved with receipt of two doses of adjuvanted vaccine and higher antigen content. (Funded by the National Institute of Allergy and Infectious Diseases.
Keywords: adjuvants; avian influenza; immunogenicity; influenza vaccine.